Ľubomíra Fábryová
The number of patients receiving lipid-lowering therapy (a combination) from year to year increases. Globally, the most
commonly prescribed lipid-lowering agents are the statins, which have become first-line drugs, as well as the cornerstone
of combination lipid-lowering therapy (statin with ezetimibe, statin with fenofibrate). In Slovakia, the situation is very
similar. In clinical practice our success depends on patient adherence and persistence to hypolipidemic treatment. Lipid-
lowering therapy (statin, statin combined with non-statin hypolipidemic agent) is well-tolerated by most patients,
the percentage of non-adherent patients is about 15 – 20 %. The most common cause of non-adherence or interruption
of lipid-lowering therapy is up 65 % due to muscle symptomatology.